Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial | BioSpace

– mahrgan

Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial | BioSpace – mahrgan

-Udenica® On-Body Injector (OBI) achieved bioequivalence in pharmacokinetics and pharmacodynamics in randomized clinical trials -Coherus plans to seek US marketing authorization for this product Udenica®OBI in 2022 Redwood City, California, October 5, 2021 (Global News Service) – Coherus BioSciences, Inc. (the “Company”; NASDAQ: CHRS) today announced a random, Open label, cross-study positive results (PK of…